A 45-year-old with neuroendocrine carcinoma of the prostate

Urology

Volumn 81, Issue 4, 2013, Pages 714-716

  Reichard, Chad ^a   Gilligan, Timothy ^b   Watts, Katherine E ^a   Magi Galluzzi, Cristina ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; TRANSURETHRAL RESECTION;

CARCINOMA, NEUROENDOCRINE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 84875525688     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.12.029     Document Type: Article

References (9)

1. D.M. Marcus, M. Goodman, and A.B. Jani A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008 Prostate Cancer Prostatic Dis 15 2012 283 288
2. M. Yashi, F. Terauchi, and A. Nukui Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review Urol Oncol 24 2006 313 317
3. G. Glück, M. Mihai, and R. Stoica Prostate cancer with neuroendocrine differentiation-case report J Med Life 5 2012 101 104
4. T. Terada Small cell neuroendocrine carcinoma of the prostate: incidence and a report of four cases with an examination of KIT and PDGFRA Prostate 72 2012 1150 1156
5. E.C. Nelson, A.J. Cambio, and J.C. Yang Clinical implications of neuroendocrine differentiation in prostate cancer Prostate Cancer Prostatic Dis 10 2007 6 14
6. D.E. Frigo, and D.P. McDonnell Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation Mol Cancer Ther 7 2008 659 669
7. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
8. M.E. Taplin, D.J. George, and S. Halabi Prognostic significance of plasma chromogranin A levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study Urology 66 2005 386 391
9. A. Berruti, M. Mosca, and M. Tucci Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease Endocr Relat Cancer 12 2005 109 117